-
Electronic (PDF)
-
Site License
-
Enterprisewide
Generalized Seizures - Pipeline Review, Q2 2011
Global Markets Direct, May 2011, Pages: 42
Generalized Seizures - Pipeline Review, Q2 2011
Summary
Global Markets Direct’s, 'Generalized Seizures - Pipeline Review, Q2 2011', provides an overview of the Generalized Seizures therapeutic pipeline. This report provides information on the therapeutic development for Generalized Seizures, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Generalized Seizures. 'Generalized Seizures - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Generalized Seizures.
- A review of the Generalized Seizures products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Generalized Seizures pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Generalized Seizures.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Generalized Seizures pipeline depth and focus of Generalized Seizures therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Generalized Seizures Overview
Therapeutics Development
An Overview of Pipeline Products for Generalized Seizures
Generalized Seizures Therapeutics under Development by Companies
Generalized Seizures Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Generalized Seizures Therapeutics - Products under Development by Companies
Generalized Seizures Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Generalized Seizures Therapeutics Development
Meiji Holdings Co., Ltd.
UCB Group
Sun Pharmaceutical Industries Limited
Jazz Pharmaceuticals, Inc.
Upsher-Smith Laboratories, Inc.
Generalized Seizures - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Vimpat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brivaracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Midazolam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Keppra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JZP-8 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lorazepam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diazepam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Midazolam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Keppra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUN 44 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ME2080 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Generalized Seizures Therapeutics – Drug Profile Updates
Generalized Seizures - Featured News
Mar 03, 2011: Eisai Receives FDA Approval For Banzel Oral Suspension, 40mg/mL
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Generalized Seizures, Q2 2011
Products under Development for Generalized Seizures – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Meiji Holdings Co., Ltd., 2011
UCB Group, 2011
Sun Pharmaceutical Industries Limited, 2011
Jazz Pharmaceuticals, Inc., 2011
Upsher-Smith Laboratories, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Generalized Seizures Therapeutics – Drug Profile Updates
List of Figures
Number of Products under Development for Generalized Seizures, Q2 2011
Products under Development for Generalized Seizures – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
